Professor Robert Langer joins Nanobiotix as Scientific Advisor
(Thomson Reuters ONE) -
Small but heading for the big time
Professor Robert Langer joins Nanobiotix as Scientific Advisor
Paris, France, 19 February, 2015 - NANOBIOTIX (Euronext: NANO - ISIN:
FR0011341205), a late clinical-stage nanomedicine company pioneering novel
approaches for the local treatment of cancer, announced that Professor Robert
Langer, Institute Professor at the Massachusetts Institute of Technology (MIT),
has become Scientific Advisor to Nanobiotix.
Laurent Levy, CEO of Nanobiotix, commented: "We really appreciate that Professor
Langer joined us as a Scientific Advisor. Professor Langer is a globally
acknowledged nanomedicine expert and serial business innovator, and his
involvement will be an asset for our technologies, our development and expansion
beyond cancer".
Professor Langer presides over the largest academic biomedical engineering
laboratory in the world. His laboratory is centered in the David H. Koch
Institute for Integrative Cancer Research at the Massachusetts Institute of
Technology. His team has more than 100 researchers including chemists,
biologists, materials science engineers and computer scientists.
He is also a Principle Investigator at the MIT-Harvard Center for Cancer
Nanotechnology Excellence, one of eight Centers of Cancer Nanotechnology
Excellence awarded by The National Cancer Institute (NCI), part of the National
Institutes of Health (NIH).
Beyond his extensive involvement and leadership in MIT's scientific community,
Professor Langer's research has spawned a vast array of innovative and
disruptive technologies. He holds over 1 000 patents in diverse areas of
biomedical technology and has been involved in the launch or acceleration of
numerous biotech companies including BIND Therapeutics, Enzytech and Pervasis as
examples.
Professor Langer said: "Radical and disruptive technologies are always required.
An interdisciplinary approach to research and development is critical to ensure
that these technologies are developed to their fullest potential. I see NanoXray
technology as one of the technologies that could make a significant difference
to disease treatment. Nanobiotix has very exciting and innovative projects and I
look forward to working with the Team".
In September 2014, Nanobiotix opened its US affiliate in the Boston Life Science
hub, in Cambridge MA. The location provides access to a critical mass of
academic and medical institutions as well as biopharmaceutical industries, and
will ensure access to the research community and clinical expertise in the US.
###
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer. The company's first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy with a view to provide a new, more efficient treatment for
cancer patients. NanoXray products are compatible with current radiotherapy
treatments and are meant to treat potentially a wide variety of cancers
including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate
Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of
administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical
development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer.
The company has partnered with PharmaEngine for clinical development and
commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in
Paris, France, opened an affiliate office in the Boston area of the US in
September, 2014.
Contact
-----------------------------------------
Nanobiotix
-----------------------------------------
Sarah Gaubert
Head of Communication and Public
Affairs
+33 (0)1 40 26 07 55
contact(at)nanobiotix.com
-----------------------------------------
Media relations
-------------------------------------------------------------------------------
France - NewCap Outside France - Instinctif Partners
Annie-Florence Loyer Melanie Toyne Sewell / Ruth Ashton
+33 (0)6 88 20 35 59 +44 (0) 207 457 2020
afloyer(at)newcap.fr nanobiotix(at)instinctif.com
Press release (PDF):
http://hugin.info/157012/R/1896022/672583.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NANOBIOTIX via GlobeNewswire
[HUG#1896022]
Datum: 19.02.2015 - 21:50 Uhr
Sprache: Deutsch
News-ID 373026
Anzahl Zeichen: 5820
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 296 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Professor Robert Langer joins Nanobiotix as Scientific Advisor"
steht unter der journalistisch-redaktionellen Verantwortung von
NANOBIOTIX (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
